Are hormone pellets safe for women? What Dr. Haver gets right

What's this video probably claiming?

Based on the caption and Dr. Mary Claire Haver's well-documented public positions, this video likely argues that testosterone pellets are being used irresponsibly in women, particularly that dosing protocols are borrowed from male hypogonadism treatment rather than calibrated for female physiology. Haver has been consistent in this criticism across her book, podcast appearances, and prior interviews. She probably walks through why pellet therapy appeals to patients (convenience, steady-state delivery) while flagging that the lack of FDA-approved testosterone products for women means practitioners are essentially improvising. Expect claims that supraphysiologic testosterone levels are common with pellets, that symptom-chasing without lab monitoring is widespread, and that women are not being adequately informed of androgenic side effects before consenting. These are legitimate concerns. They are also concerns that have been raised in peer-reviewed literature, not just by influencer physicians.

What does the science actually show?

The concern about supraphysiologic dosing is not hypothetical. A 2019 study by Glaser and Dimitrakakis in Maturitas reported pellet doses for women ranging from 75 mg to 225 mg of testosterone, while a 2014 consensus statement published in Nature Reviews Endocrinology (Davis et al.) specified that physiologic testosterone levels in premenopausal women sit between roughly 15 and 70 ng/dL. Studies tracking pellet recipients have documented post-insertion peaks well above 200 ng/dL in some patients, which is within the low-normal male range. Androgenic side effects including acne, clitoral enlargement, voice deepening, and hair thinning are dose-dependent and partially irreversible. The 2019 Global Consensus Position Statement on testosterone therapy for women, published in The Journal of Clinical Endocrinology and Metabolism, explicitly states that pellets cannot currently be recommended because they lack pharmacokinetic data supporting safe, consistent dosing in women. That is a hard line from the major endocrinology and menopause societies, not a fringe opinion.

Where does the social media noise diverge from clinical reality?

The pellet industry has a marketing problem masquerading as a science problem. Practitioners selling pellet insertion as a premium wellness service have strong financial incentives to downplay the dosing concerns the Global Consensus raised. On TikTok and Instagram, you will find plenty of before-and-after testimonials attributing energy, libido, and mood improvements to pellets specifically, when the honest answer is that any testosterone supplementation bringing a genuinely deficient woman to physiologic levels would likely produce similar benefits. The delivery mechanism is not magic. What pellets do offer is convenience and a relatively stable serum level after the initial peak, but that initial peak is exactly what the critics are worried about. The problem is that the wellness-clinic ecosystem has adopted pellets faster than regulators or researchers can audit outcomes. Dr. Haver is correct to raise the alarm, but it is worth noting that even transdermal testosterone, which does have stronger evidence support, remains off-label for women in the United States.

What should you actually know?

If a provider recommends testosterone pellets, ask four specific questions before agreeing. First, what is the target serum testosterone level post-insertion, and how will it be monitored? Second, what is the insertion dose in milligrams, and how does it compare to the physiologic female range? Third, which side effects are partially irreversible, and at what threshold will therapy be adjusted or stopped? Fourth, what is the plan if levels come in above target after insertion, because unlike a gel or patch, a pellet cannot be removed. The 2019 Global Consensus recommends total testosterone levels remain below the upper limit of the normal female range, approximately 70 ng/dL, and that monitoring occur at 3 to 6 weeks post-initiation. Any practice that does not offer this monitoring is operating outside published guidance. Testosterone can genuinely help some women. The question is whether the delivery system and dose are appropriate, not whether the hormone itself has a role.